ArticleClinical rheumatology2025
Investigating the potential impact of gut microbiota and immune cells on ankylosing spondylitis based on single-cell sequencing and genetic variation analysis.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectivesSeveral observational studies suggest that gut microbiota (GM) may influence the onset and progression of ankylosing spondylitis (AS) through modulating host immune responses. However, the potential genetic associations between GM and AS susceptibility, as well as the immune-mediated mechanisms, remain to be elucidated.
methodThis study initially infers the causal associations among GM, immune cell traits (ICTs), and AS using univariate two-sample Mendelian randomization (MR), and then evaluates the mediating role of ICTs in the genetic association between GM and AS through mediation MR analysis. Meanwhile, single-cell RNA sequencing is conducted on vertebral bone marrow blood samples obtained from three AS patients and three controls to characterize the differentiation status and functional alterations of relevant immune cell subsets, thereby validating their contribution to the pathogenesis of AS.
resultMediation MR analysis revealed that "HLA-DR on CD14- CD16 + monocytes" acts as a protective factor for AS, attenuating the causal effect of Genus Sutterella/Sutterella Wadsworthensis on disease susceptibility. Single-cell analysis revealed distinct differences in cellular composition and transcriptional profiles between AS and the controls. Notably, monocyte subset analysis indicated a significant reduction in CD14- CD16 + monocytes in AS, concomitant with the relatively high expression of cellular activation markers.
conclusionThe study indicates that CD14- CD16 + monocytes are potential protective factors for AS and exert a negative mediating effect on the causal associations between GM and AS. Boosting non-classical monocytes or modulating Sutterella abundance could help prevent or treat AS. Key Points • Novel approach integrating mediation MR and scRNA-seq offers distinct analytical strengths. • New insights into the gut-immune axis reveal its role in immune dysregulation in AS. • Mediation MR and single-cell analysis reveals CD14- CD16 + monocytes as protective factors in AS. • HLA-DR on CD14- CD16 + monocytes mitigate the genetic effect of Sutterella on AS susceptibility.
Indexed as
Identifiers
40824341What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.